XML 59 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended
Apr. 18, 2022
Apr. 30, 2022
Mar. 31, 2018
Dec. 31, 2022
Sep. 30, 2022
Dec. 31, 2021
Dec. 31, 2020
Oct. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Acquisitions                    
Goodwill       $ 3,301,959 $ 3,214,747   $ 1,452,338      
Pelican Therapeutics, Inc.                    
Acquisitions                    
Ownership interest in subsidiary       85.00%   85.00%   85.00% 80.00%  
Pelican Therapeutics, Inc.                    
Acquisitions                    
Percentage of voting interests acquired in acquisition                   80.00%
Cash consideration     $ 200,000              
Milestone payment       $ 0            
Pelican Therapeutics, Inc. | Stockholders                    
Acquisitions                    
Cash consideration     $ 300,000              
Elusys Therapeutics                    
Acquisitions                    
Earn out payments period 12 years                  
Percentage of earn out payments 10.00%                  
Frequency of periodic earn out payment 1 year                  
Period of occurrence of earn payment 9 years                  
Receivable consideration $ 22,318,685                  
Consideration paid   $ 20,800,000                
Holding back related to future fulfillment cost   $ 1,500,000                
Contract receivables 24,526,232                  
Fair value of the purchase consideration 42,900,000                  
Cash consideration 3,000,000                  
Deferred cash consideration 2,000,000                  
Fair value of contingent and deferred consideration liabilities $ 37,900,000                  
Discount rate for deferred consideration 24.00%                  
Discount rate for earn out liabilities 14.00%                  
Preliminary value of Additional Earn Out liability as percentage 80.00%                  
Goodwill $ 3,301,960                  
Goodwill deductible for tax purposes 15 years